id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S10172 R37178 |
Blotière (Phenobarbital) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2019 | Craniosynostosis | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
37.69 [0.74;1911.73] C excluded (control group) |
0/80 0/2,997 | 0 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S10042 R36314 |
Blotière (Phenobarbital) (Controls unexposed NOS) (Mixed indications), 2019 | Craniosynostosis | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 15.38 [0.95;248.35] C | 0/80 766/1,875,733 | 766 | 80 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9101 R31188 |
D'Souza (Phenobarbital) (Controls unexposed, disease free), 1991 | Cranyosynostosis (saggital suture) | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
17.57 [0.30;1024.08] C excluded (control group) |
0/4 0/62 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9102 R31217 |
D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 | Cranyosynostosis (saggital suture) | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.14 [0.03;131.94] C | 0/4 0/8 | 0 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 8.30 [0.83;83.23] | 766 | 84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed NOS) (Mixed indications; 2: Phenobarbital) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9101, 10172